CN114767644A - 稳定的40-o-(2-羟乙基)-雷帕霉素片剂及其制备方法 - Google Patents
稳定的40-o-(2-羟乙基)-雷帕霉素片剂及其制备方法 Download PDFInfo
- Publication number
- CN114767644A CN114767644A CN202210596853.0A CN202210596853A CN114767644A CN 114767644 A CN114767644 A CN 114767644A CN 202210596853 A CN202210596853 A CN 202210596853A CN 114767644 A CN114767644 A CN 114767644A
- Authority
- CN
- China
- Prior art keywords
- hydroxyethyl
- rapamycin
- tablet
- weight
- organic solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 title claims abstract description 75
- 238000004519 manufacturing process Methods 0.000 title description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 37
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 25
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 25
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 25
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000000463 material Substances 0.000 claims abstract description 17
- 239000003960 organic solvent Substances 0.000 claims abstract description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000000853 adhesive Substances 0.000 claims abstract description 13
- 230000001070 adhesive effect Effects 0.000 claims abstract description 13
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 11
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 11
- 239000000945 filler Substances 0.000 claims abstract description 11
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical group CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000000314 lubricant Substances 0.000 claims abstract description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims abstract description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 5
- 229940069328 povidone Drugs 0.000 claims abstract description 4
- 239000002994 raw material Substances 0.000 claims abstract description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 20
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 17
- 235000019359 magnesium stearate Nutrition 0.000 claims description 14
- 229960004977 anhydrous lactose Drugs 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 13
- 239000007962 solid dispersion Substances 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 6
- 238000005507 spraying Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 229960002930 sirolimus Drugs 0.000 claims description 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 229960001021 lactose monohydrate Drugs 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 230000006641 stabilisation Effects 0.000 claims description 2
- 238000011105 stabilization Methods 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 229960004793 sucrose Drugs 0.000 claims description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 238000004090 dissolution Methods 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 13
- 239000008187 granular material Substances 0.000 description 13
- 238000001035 drying Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 3
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229960005167 everolimus Drugs 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229920001531 copovidone Polymers 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 238000001159 Fisher's combined probability test Methods 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010074268 Reproductive toxicity Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229940022682 acetone Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000009474 hot melt extrusion Methods 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000007696 reproductive toxicity Effects 0.000 description 1
- 231100000372 reproductive toxicity Toxicity 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000009999 tuberous sclerosis Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
组成 | 批量/g |
40-O-(2-羟乙基)-雷帕霉素 | 15 |
2,6-二叔丁基-4-甲基苯酚 | 0.3 |
羟丙甲纤维素 | 60 |
羟丙甲纤维素 | 75 |
无水乳糖 | 595.95 |
硬脂酸镁 | 3.75 |
丙酮、无水乙醇混合液(1:1) | 750 |
组成 | 批量/g |
40-O-(2-羟乙基)-雷帕霉素 | 15 |
2,6-二叔丁基-4-甲基苯酚 | 0.3 |
羟丙甲纤维素 | 30 |
羟丙甲纤维素 | 105 |
无水乳糖 | 595.95 |
硬脂酸镁 | 3.75 |
丙酮、无水乙醇混合液(1:1) | 1200 |
组成 | 用量/g |
40-O-(2-羟乙基)-雷帕霉素 | 5 |
共聚维酮 | 25 |
甘露醇 | 96.4 |
喷雾干燥乳糖 | 90 |
交联聚维酮 | 30 |
硬脂酸镁 | 3.6 |
组成 | 用量/g |
40-O-(2-羟乙基)-雷帕霉素 | 5 |
二丁基羟基甲苯 | 0.1 |
丙酮 | 适量 |
无水乙醇 | 适量 |
羟丙甲纤维素 | 45 |
乳糖 | 4.9 |
交联聚维酮 | 20 |
无水乳糖 | 173.75 |
硬脂酸镁 | 1.25 |
组成 | 批量/g |
40-O-(2-羟乙基)-雷帕霉素 | 15 |
2,6-二叔丁基-4-甲基苯酚 | 0.3 |
羟丙甲纤维素 | 30 |
羟丙甲纤维素 | 105 |
无水乳糖 | 595.95 |
硬脂酸镁 | 3.75 |
无水乙醇 | 750 |
样品 | 实施例1 | 实施例2 | 对比例1 | 对比例2 |
A+2.2S | 1.79 | 2.28 | 10.73 | 11.35 |
样品 | 实施例1 | 实施例2 | 对比例1 | 对比例2 |
休止角 | 27° | 29° | 41° | 39° |
样片 | 0时 | 3时 | 4.5h | 6h |
实施例1 | 1.1% | 1.4% | 1.6% | 1.7% |
对比例2 | 2.0% | 3.7% | 4.1% | 5.3% |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210596853.0A CN114767644A (zh) | 2022-05-30 | 2022-05-30 | 稳定的40-o-(2-羟乙基)-雷帕霉素片剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210596853.0A CN114767644A (zh) | 2022-05-30 | 2022-05-30 | 稳定的40-o-(2-羟乙基)-雷帕霉素片剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114767644A true CN114767644A (zh) | 2022-07-22 |
Family
ID=82408924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210596853.0A Pending CN114767644A (zh) | 2022-05-30 | 2022-05-30 | 稳定的40-o-(2-羟乙基)-雷帕霉素片剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114767644A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104721158A (zh) * | 2013-12-24 | 2015-06-24 | 正大天晴药业集团股份有限公司 | 一种稳定的依维莫司片剂 |
-
2022
- 2022-05-30 CN CN202210596853.0A patent/CN114767644A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104721158A (zh) * | 2013-12-24 | 2015-06-24 | 正大天晴药业集团股份有限公司 | 一种稳定的依维莫司片剂 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107595784B (zh) | 他克莫司缓释药物组合物 | |
EP1982702A1 (en) | Sirolimus formulation | |
CN109674754B (zh) | 一种氟哌噻吨美利曲辛药物组合物及其制剂 | |
CN109771386B (zh) | 一种氟哌噻吨美利曲辛片剂及其制备方法 | |
WO2017064039A1 (en) | Afatinib-containing formulation | |
CN108030924B (zh) | 一种高稳定性阿瑞匹坦组合物的制备方法 | |
CN107753455B (zh) | 一种含有咪达那新的片剂及其制备方法 | |
CN114767644A (zh) | 稳定的40-o-(2-羟乙基)-雷帕霉素片剂及其制备方法 | |
CN110638768B (zh) | 一种治疗男性勃起功能障碍药物的制备方法 | |
CN104721158A (zh) | 一种稳定的依维莫司片剂 | |
CN114917233B (zh) | 一种包含核苷类似物的药物组合物及其制备方法和应用 | |
CN113827576B (zh) | 一种活性成分为草酸纳洛解的药物组合物及制备方法 | |
CN112023056B (zh) | 一种氟康唑药物组合物及其制备方法 | |
CN106880597B (zh) | 一种依维莫司片 | |
CN102462667A (zh) | 一种硫酸氢氯吡格雷片剂 | |
KR101794573B1 (ko) | 콜린알포세레이트를 포함하는 속방출형 고형제제 및 이의 제조방법 | |
CN106860407B (zh) | 一种利伐沙班片 | |
CN106265557A (zh) | 含有替格瑞洛的药物组合物 | |
CN113209036B (zh) | 一种阿齐沙坦片及其制备方法和应用 | |
CN112315914A (zh) | 一种来那度胺药物组合物及其制备方法 | |
CN111603450B (zh) | 一种单硝酸异山梨酯片剂及其制备工艺 | |
CN106309387B (zh) | 一种依维莫司片剂 | |
JPH11335302A (ja) | 安定な医薬組成物 | |
CN115770226B (zh) | 一种非布司他片及其制备方法 | |
CN108938584B (zh) | 一种含VEGF受体抑制剂Tivozanib盐的片剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20221206 Address after: No. 24, Chengdong Road, Xiaofeng Town, Anji County, Huzhou City, Zhejiang Province Applicant after: Hangzhou Huadong Medicine Group Kangrun Pharmaceutical Co.,Ltd. Applicant after: HANGZHOU ZHUYANGXIN PHARMACEUTICAL Co.,Ltd. Address before: 310018 No.10, No.11 street, Hangzhou Economic and Technological Development Zone, Hangzhou, Zhejiang Province Applicant before: HANGZHOU ZHUYANGXIN PHARMACEUTICAL Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
CB02 | Change of applicant information |
Address after: No. 24, Chengdong Road, Xiaofeng Town, Anji County, Huzhou City, Zhejiang Province Applicant after: Zhejiang Kangrun Pharmaceutical Co.,Ltd. Applicant after: HANGZHOU ZHUYANGXIN PHARMACEUTICAL Co.,Ltd. Address before: No. 24, Chengdong Road, Xiaofeng Town, Anji County, Huzhou City, Zhejiang Province Applicant before: Hangzhou Huadong Medicine Group Kangrun Pharmaceutical Co.,Ltd. Applicant before: HANGZHOU ZHUYANGXIN PHARMACEUTICAL Co.,Ltd. |
|
CB02 | Change of applicant information |